General Gastro News Articles

Gastro

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Marks DH et al. - Studies have shown a negative contribution of many underlying and or concurrent medical conditions to the response rate for HCV. Several of these co-morbid conditions (DM, HTN, obesity, elevated cholesterol) have a particularly high prevalence in the AA community.

Exclusive Author Commentary
Donald H. Marks, MD PhD, 07/01/09

Most studies comparing the response of African American (AA) patients to other groups for treatment of hepatitis C virus (HCV) have been performed in academic centers in the setting of clinical trials. In general, AA patients have lower response rates that are only partially explained by unfavorable prognostic factors, such as infection with genotype 1, high viral load, insulin resistance, obesity, hypertension, and others. We examined response rates associated with these adverse prognostic factors within race/ethnicity-sex strata for a cohort of patients treated at a inner -city hospital-based, safety-net clinic. From 2004-2008, 88 evaluable AA and 30 other patients received standard therapy for HCV consisting of weekly injections of peg interferon alfa-2 plus oral weight-based ribavirin. The predicted probability of a favorable virologic outcome ranged from 89.0% (95% CI: 63.7% = 97.3%) for other females to 4.1% (95% CI: 0.9% - 17.9%) for AA females. We concluded that important interactions occur among race/ethnicity, sex, and co-morbidity in response to HCV therapy. Increasing co-morbidity places AA patients at greatest risk of nonresponse and raises the possibility that more aggressive treatment of co-morbidity might increase response rates in the vulnerable patients.

Related Articles

Acute hepatitis C and HIV coinfection
The Lancet Infectious Diseases, 11/19/09    Relevance Score: 70%

De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation
Liver Transplantation, 10/30/09    Relevance Score: 70%

Treatment modalities for hypersplenism in liver transplant recipients with recurrent hepatitis C
World Journal of Gastroenterology, 10/30/09    Relevance Score: 70%

FOXP3 Expression in Hepatitis C Virus-Specific CD4+ T Cells During Acute Hepatitis C
Gastroenterology, 10/06/09    Relevance Score: 70%

Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial
Hepatology, 10/14/09    Relevance Score: 69%

Today in Hepatology...keeping you current

The Influence of Induction Therapy on Graft and Patient Survival in Patients with and without Hepatitis C after Liver Transplantation
American Journal of Transplantation, 12/08/09

Hypothermic Machine Preservation in Human Liver Transplantation: The First Clinical Series
American Journal of Transplantation, 12/08/09

Inhibition of hepatoma 22 tumor by Liquiritigenin
Phytotherapy Research, 12/08/09